Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...

But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI ...

In recent years, Artificial Intelligence (AI) has made significant strides across various sectors, providing innovative solutions and enhancing efficiency. However, ...

The Food and Drug Administration's new AI tool, Elsa, is reportedly generating false studies, raising concerns about the ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

“If the question is, can AI replace a human reviewer, I would say absolutely not,” said Jason Conaty, counsel in the Los Angeles office of Hogan Lovells who specializes in drug regulatory affairs.

On April 10, 2025, the U.S. Food and Drug Administration (FDA) announced a landmark initiative to phase out animal testing in ...

Hallucinations are a known problem with generative AI models—and Elsa is no different, according to Jeremy Walsh, the head of ...

For decades, Alzheimer’s disease has resisted nearly every significant pharmaceutical intervention. Despite billions invested and a growing aging population, most drug candidates have failed during ...

"As we learn those molecular signatures across diverse populations, we can understand their unique biology," Curtis said. Continue on to Part 2 and Part 3of AI's Drug Revolution.

The FDA's generative AI, Elsa, has a massive hallucination problem, according to the agency's employees themselves.

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...